NO20034322D0 - Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister - Google Patents

Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister

Info

Publication number
NO20034322D0
NO20034322D0 NO20034322A NO20034322A NO20034322D0 NO 20034322 D0 NO20034322 D0 NO 20034322D0 NO 20034322 A NO20034322 A NO 20034322A NO 20034322 A NO20034322 A NO 20034322A NO 20034322 D0 NO20034322 D0 NO 20034322D0
Authority
NO
Norway
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
NO20034322A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034322L (no
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20034322L publication Critical patent/NO20034322L/no
Publication of NO20034322D0 publication Critical patent/NO20034322D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20034322A 2001-04-30 2003-09-26 Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister NO20034322D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (2)

Publication Number Publication Date
NO20034322L NO20034322L (no) 2003-09-26
NO20034322D0 true NO20034322D0 (no) 2003-09-26

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034322A NO20034322D0 (no) 2001-04-30 2003-09-26 Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322D0 (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
CN1186326C (zh) * 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
UA83928C2 (ru) 2004-06-04 2008-08-26 Астеллас Фарма Инк. Производное пропан-1,3-диона или его соль
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CN101087618A (zh) * 2004-12-23 2007-12-12 航行药物公司 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
EP2535336A1 (en) 2006-10-21 2012-12-19 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009033781A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009040006A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Spantide for therapeutic uses
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
JP2000511532A (ja) 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
MXPA01011634A (es) 1999-05-14 2002-07-30 Neurocrine Biosciences Inc Imidazo- y pirrolo [1,2-a]pirimid-4-onas como antagonistas receptores de la hormona liberadora de gonadotropina.
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
CA2386942A1 (en) 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP1393747A1 (en) 2000-04-13 2004-03-03 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
CN1186326C (zh) 2000-07-05 2005-01-26 山之内制药株式会社 丙－1,3－二酮衍生物

Also Published As

Publication number Publication date
CA2444876A1 (en) 2002-12-27
IL156777A0 (en) 2004-02-08
SK14512003A3 (sk) 2004-08-03
BR0209290A (pt) 2004-07-13
CN1317030C (zh) 2007-05-23
ES2307760T3 (es) 2008-12-01
HK1072000A1 (en) 2005-08-12
KR20040000446A (ko) 2004-01-03
PL362319A1 (en) 2004-10-18
NO20034322L (no) 2003-09-26
UA80679C2 (en) 2007-10-25
BG108339A (bg) 2004-11-30
CN1575185A (zh) 2005-02-02
ATE400287T1 (de) 2008-07-15
EP1392348B1 (en) 2008-07-09
JP2004529207A (ja) 2004-09-24
NZ544417A (en) 2008-03-28
MXPA03008666A (es) 2004-10-15
US7288517B2 (en) 2007-10-30
PT1392348E (pt) 2008-09-09
AU2002310788B2 (en) 2007-04-05
SI1392348T1 (sl) 2008-12-31
US20020177556A1 (en) 2002-11-28
RU2003134949A (ru) 2005-02-10
EP1392348A1 (en) 2004-03-03
DK1392348T3 (da) 2008-09-29
DE60227507D1 (de) 2008-08-21
WO2002102401A1 (en) 2002-12-27
ZA200305326B (en) 2003-07-30
RU2319501C2 (ru) 2008-03-20
HUP0400067A2 (hu) 2004-04-28
CZ20033167A3 (cs) 2004-08-18

Similar Documents

Publication Publication Date Title
NO20034322D0 (no) Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister
TR200001608T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
LTPA2015001I1 (lt) Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai
WO2002002506A8 (en) Compounds to treat alzheimer's disease
NO20026199D0 (no) Forbindelser for behandling av Alzheimers sykdom
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
TNSN04165A1 (en) Substituted hydroxyethylamines
EA200301223A1 (ru) Лекарственные формы окскарбазепина
DE60144514D1 (de) Verwendung von il-18 inhibitoren
JO2207B1 (en) Pharmaceutical radiological compounds to diagnose Alzheimer's disease
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
NO20000771D0 (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
BR0000486A (pt) Antagonistas do neuropeptìdeo y
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
DE60117541D1 (de) Candesartan zur Behandlung von Migräne
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
NO20033634D0 (no) GLYT-1 inhibitorer
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease
HK1063639A (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2002319451A1 (en) Therapeutic strategies for prevention and treatment of alzheimer's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application